Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, which will see it add microparticle capabilities to its portfolio of drug delivery technologies. Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three separate $50m milestone payments. Elektrofi will receive these payments if three products, which are currently undisclosed, are approved following the takeover. Elektrofi’s platform, called Hyercon, cr ...

Group 1 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is considered one of the best biotech stocks to buy, with Benchmark maintaining a Buy rating and increasing the price target from $75 to $90 due to favorable financial forecasts and solid earnings results for the first half of 2025 [1][2] - Benchmark's revised price target is based on the expectation that Halozyme's projected 2025 revenues will be 8.5 times higher, highlighting the company's growth potential [2] - The FDA recently approved Merck's Keytruda Qlex, which utilizes an enzyme licensed from Alteogen that competes with Halozyme's Enhanze enzyme, leading to ongoing patent disputes between the two companies [2][3] Group 2 - Halozyme Therapeutics operates as a biopharmaceutical technology platform company, focusing on creating, manufacturing, and selling drug-device combination solutions using advanced auto-injector technologies [3]